3671.T

The company maintains a strong liquidity position, with cash and equivalents amounting to ¥3.12 billion, representing 34.15% of total assets. Its liquidity FPT (free cash flow to total liabilities) is 0.078, indicating a moderate ability to service liabilities from operating cash flows. The current ratio of 1.55 suggests the company can cover its short-term obligations with its current assets.

Profitability metrics show a return on equity (ROE) of 14.61%, which is above the industry median of 12.3% for IT Services & Consulting firms. Return on assets (ROA) stands at 6.28%, also exceeding the industry median of 5.1%. The company's operating margin of 10.68% is in line with the industry median of 10.4%, indicating efficient cost management.

The company's revenue is concentrated in the health care technology segment, as per its sector classification industry classification. No geographic revenue breakdown is available in the provided data, but the company's primary operations are based in Japan. This concentration may expose the company to regional economic and regulatory risks.

Outlook data indicates a projected revenue growth of 3.2% for the current fiscal year and 4.1% for the next fiscal year. This growth is supported by the company's expansion in digital health solutions and increased demand for IT consulting in the health care sector.

Risk assessment reveals a low liquidity risk and a low dilution risk. The company has no immediate filing-based liquidity or dilution flags. The debt-to-equity ratio of 0.63 suggests a conservative capital structure, with long-term debt at ¥2.48 billion and total equity at ¥3.93 billion.

Recent events include the company's Q4 2023 earnings report, which highlighted strong performance in the health care IT segment. The company also announced a new partnership with a major health care provider to develop AI-driven diagnostic tools.